Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Controls severe or incapacitating allergic conditions. Sold as Hydeltrasol, Pediapred, Orapred Odt. Every FDA application for this active ingredient: 4 branded and 35 generic.
As of Nov 15, 2026, FDA lists 39 applications for Prednisolone Sodium Phosphate (sold as Hydeltrasol, Pediapred, Orapred Odt), first approved May 28, 1986, with 1 new use approved and 0 published complete response letters.
First approved: May 28, 1986
Applications: 39
New uses approved: 1
Complete response letters: 0
Medicare spending, 2025: $1.1M
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Prednisolone Sodium Phosphate
Part D
$1.1M
+20%
28,129
Prednisolone Sodium Phos ODT
Part D
$24K
-65%
63
Orapred ODT
Part D
$18K
New
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
PREDNISOLONE 10 MG/5 ML SOLN: $2.43 per MLGeneric · -9% in a year
PREDNISOLONE 15 MG/5 ML SOLN: $0.540 per MLGeneric · -2% in a year
PREDNISOLONE 15 MG/5 ML SYRUP: $0.573 per MLGeneric · -5% in a year
PREDNISOLONE 5 MG TABLET: $8.30 per unitGeneric · -14% in a year
PREDNISOLONE 5 MG/5 ML SOLN: $0.549 per MLGeneric · -1% in a year
PrednisoloneDrugs with revised indications and a new dosage for the treatment of malignant lymphoma and similar diseases (closely-related diseases). · Shionogi & Co., Ltd. · Jun 26, 2015
PredonineDrugs with a new indication for the treatment of multiple myeloma. · Takeda Pharmaceutical Company Limited · Sep 16, 2011
Clinical Trials
350 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA
Novartis
Hikma
Schering